Holen Sie sich die Stockscreener-App
22.42
4.74%
-1.20
Schlusskurs vom Vortag:
$23.62
Offen:
$23.73
24-Stunden-Volumen:
320.48K
Relative Volume:
0.39
Marktkapitalisierung:
$2.52B
Einnahmen:
$14.09M
Nettoeinkommen (Verlust:
$-176.94M
KGV:
-10.43
EPS:
-2.15
Netto-Cashflow:
$-141.24M
1W Leistung:
+3.16%
1M Leistung:
+15.62%
6M Leistung:
+11.44%
1J Leistung:
+43.68%
1-Tages-Spanne:
$22.26
$23.85
1-Wochen-Bereich:
$21.14
$23.85
52-Wochen-Spanne:
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Firmenname
Newamsterdam Pharma Company Nv
Sektor
Branche
Telefon
35 206 2971
Adresse
GOOIMEER 2-35, NARRDEN
Vergleichen Sie NAMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
22.47 | 2.44B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
377.71 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.66 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.63 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
668.20 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
296.01 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-17 | Eingeleitet | Goldman | Neutral |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-06-10 | Eingeleitet | Stifel | Buy |
| 2025-06-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-15 | Eingeleitet | TD Cowen | Buy |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-18 | Eingeleitet | Guggenheim | Buy |
| 2024-01-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-30 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
NewAmsterdam Pharma Second Quarter 2025 Earnings: US$0.15 loss per share (vs US$0.41 loss in 2Q 2024) - uk.finance.yahoo.com
NewAmsterdam Pharma earnings beat by $0.35, revenue topped estimates - Investing.com UK
NewAmsterdam Pharma Reports Q2 2025 Financial Results - TipRanks
NewAmsterdam (NAMS) Q2 Revenue Jumps 49% - The Motley Fool
Newamsterdam Pharma shares rise 6.12% intraday as Q2 net loss narrows and revenue rises. - AInvest
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates - sharewise.com
NewAmsterdam Pharma Q2 Net Loss Narrows, Revenue Rises - MarketScreener
NewAmsterdam Pharma Company NV reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (NAMS) NewAmsterdam Pharma Company N.V. Reports Q2 Revenue $19.1M, vs. FactSet Est of $1.9M - MarketScreener
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - GlobeNewswire
NewAmsterdam Pharma Co N.V. SEC 10-Q Report - TradingView
Is NewAmsterdam Pharma Company N.V. Equity Warrant the Top Chart Pick This WeekHigh Conviction Intraday Stock Signals Detected - beatles.ru
Published on: 2025-08-04 14:31:37 - metal.it
What is the dividend policy of NewAmsterdam Pharma Company N.V. stockInvest confidently with daily market forecasts - Jammu Links News
What drives NewAmsterdam Pharma Company N.V. stock priceExponentially increasing returns - Jammu Links News
Should I hold or sell NewAmsterdam Pharma Company N.V. stock in 2025Discover stocks with massive upside potential - Jammu Links News
Is NewAmsterdam Pharma Company N.V. Equity Warrant a growth stock or a value stockTurn market volatility into profit opportunities - Jammu Links News
What are the technical indicators suggesting about NewAmsterdam Pharma Company N.V.Build a portfolio with strong long-term growth - Jammu Links News
What are the latest earnings results for NewAmsterdam Pharma Company N.V.Accelerated wealth building - jammulinksnews.com
What institutional investors are buying NewAmsterdam Pharma Company N.V. Equity Warrant stockFree Technical Analysis Support - Jammu Links News
Why is NewAmsterdam Pharma Company N.V. Equity Warrant stock attracting strong analyst attentionExceptional profit margins - Jammu Links News
What are the latest earnings results for NewAmsterdam Pharma Company N.V. Equity WarrantBoost your returns with professional guidance - jammulinksnews.com
What is NewAmsterdam Pharma Company N.V. company’s growth strategyExceptional profit potential - Jammu Links News
What are NewAmsterdam Pharma Company N.V. Equity Warrant company’s key revenue driversCapitalize on emerging investment opportunities - Jammu Links News
What are NewAmsterdam Pharma Company N.V. company’s key revenue driversDiscover the fastest growing stocks today - Jammu Links News
Is it the right time to buy NewAmsterdam Pharma Company N.V. Equity Warrant stockFree Stock Market Return Analysis - Jammu Links News
Published on: 2025-08-04 00:09:00 - Jammu Links News
When is NewAmsterdam Pharma Company N.V. stock expected to show significant growthStay ahead with daily market updates - Jammu Links News
Should I hold or sell NewAmsterdam Pharma Company N.V. Equity Warrant stock in 2025Game-changing returns - Jammu Links News
What drives NewAmsterdam Pharma Company N.V. Equity Warrant stock priceTap into rapid wealth building techniques - Jammu Links News
How strong is NewAmsterdam Pharma Company N.V. Equity Warrant company’s balance sheetCapitalize on market trends with expert guidance - Jammu Links News
Published on: 2025-08-03 11:05:58 - Jammu Links News
Published on: 2025-08-03 06:39:53 - Jammu Links News
What is the risk reward ratio of investing in NewAmsterdam Pharma Company N.V. Equity Warrant stockTurn market volatility into profit opportunities - Jammu Links News
What makes NewAmsterdam Pharma Company N.V. Equity Warrant stock price move sharplyInvest smarter with data-backed insights - Jammu Links News
What are analysts’ price targets for NewAmsterdam Pharma Company N.V. in the next 12 monthsPre Market Entry Points To Watch Now - Jammu Links News
Does NewAmsterdam Pharma Company N.V. qualify in momentum factor screeningReal-Time Analysis With Entry Targets In Progress - metal.it
What institutional investors are buying NewAmsterdam Pharma Company N.V. stockRetirement Planning Guidance To Watch Now - jammulinksnews.com
Transcript : NewAmsterdam Pharma Company N.V.Special Call - MarketScreener
Can NewAmsterdam Pharma Company N.V. recover in the next quarterDaily Growth Stock Pick Reports Show Bullish Signals - metal.it
In Broadway trial, a hopeful tune for Alzheimer’s prevention - BioWorld MedTech
NewAmsterdam Pharma Company N.V. Presents Positive Data from Br Broadway Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers At Aaic 2025 - MarketScreener
Will NewAmsterdam Pharma Company N.V. Reverse From Oversold ConditionsReal-Time Trade Insights Spark Market Reactions - metal.it
NewAmsterdam Pharma Presents Positive Data from BROADWAY - GlobeNewswire
Frazier Lifesciences Acquisition : NewAmsterdam Pharma Alzheimers Analysis (1) - MarketScreener
NewAmsterdam Pharma’s Promising Phase 3 Alzheimer’s Trial Results - TipRanks
Finanzdaten der Newamsterdam Pharma Company Nv-Aktie (NAMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):